Joseph P. Lyssikatos Sells 847 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 847 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $25,410.00. Following the sale, the insider now owns 1,015,188 shares in the company, valued at approximately $30,455,640. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Stock Up 0.3 %

Shares of Enliven Therapeutics stock traded up $0.08 on Tuesday, hitting $28.95. The stock had a trading volume of 152,952 shares, compared to its average volume of 260,665. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $30.03. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -14.96 and a beta of 1.10. The stock’s 50-day simple moving average is $24.23 and its two-hundred day simple moving average is $22.77.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently modified their holdings of the stock. Janus Henderson Group PLC raised its position in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares during the last quarter. First Turn Management LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth about $9,657,000. Marshall Wace LLP purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth about $4,489,000. Baker BROS. Advisors LP purchased a new position in Enliven Therapeutics in the 1st quarter worth about $2,020,000. Finally, Bank of New York Mellon Corp raised its position in Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after buying an additional 37,632 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.